How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?

А im: to analyze the main pharmacokinetic properties of proton pump inhibitors (PPIs) and their significance in treatment gastroesophageal reflux disease (GERD). Key points. Pantoprazole has a high bioavailability, absolute bioavailability pantoprazole at dose 40 mg is 77 % from first does not change with repeated use. shows faster onset action than omeprazole. Simultaneous food intake pantoprazole. Suppression hydrochloric acid production while taking accompanies by achievement endoscopic remission GERD day 28 91 patients esophagitis 56 all PANSTAR studies. little effect on CYP2C19 compared other PPIs, minimizing risk drug-drug interactions. most pH-selective PPI, which determines specificity only parietal cells stomach greatest safety long-term use comorbid pathology. Conclusion. PPIs form basis therapy acid-dependent diseases, and, particular, disease. distinguished its persistent antisecretory effect, very low affinity for cytochrome P450.